Fusidic acid betamethasone lipid cream

Autor: S Manfredini, R Mattina, S Vertuani, G. Fabrizi, Giampiero Girolomoni
Rok vydání: 2016
Předmět:
Medicine (all)
cosmetics
dermatology
antinflammatory
antibacterial

Staphylococcus aureus
medicine.medical_specialty
antinflammatory
Impetigo
Fusidic
medicine.drug_class
Fusidic acid
Secondary infection
Antibiotics
Anti-Inflammatory Agents
Fusidic
acid betamethasone

Folliculitis
Administration
Cutaneous

medicine.disease_cause
Betamethasone
Dermatitis
Atopic

NO
Microbiology
Ointments
030207 dermatology & venereal diseases
03 medical and health sciences
Drug Delivery Systems
0302 clinical medicine
Risk Factors
medicine
Humans
030212 general & internal medicine
acid betamethasone
cosmetics
business.industry
Medicine (all)
General Medicine
Atopic dermatitis
medicine.disease
Dermatology
Anti-Bacterial Agents
dermatology
Drug Combinations
antibacterial
Staphylococcal Skin Infections
Dermatologic Agents
business
Fusidic Acid
medicine.drug
Zdroj: International Journal of Clinical Practice. 70:4-13
ISSN: 1368-5031
DOI: 10.1111/ijcp.12808
Popis: Bacterial infections of the skin and soft tissues are frequent disorders. They can be primitive infections (e.g. impetigo, folliculitis) or secondary infections complicating other diseases, particularly atopic dermatitis. The most common aetiologic agent is Staphylococcus aureus. Topical antibiotic therapy may be sufficient in many instances to control these infections. Fusidic acid is an antibiotic used topically on the skin which is very active against S. aureus, including methicillin-resistant strains, and other Gram-positive bacteria. Resistance rates to fusidic acid are stably low. A fusidic acid and betamethasone formulation in a lipid-enriched cream (lipid cream) has been recently developed in order to provide effective antibacterial and anti-inflammatory activities in conjunction with a powerful emollient and moisturising effect. This preparation may be especially useful in patients with atopic-infected eczema.
Databáze: OpenAIRE